Q/C Technologies, Inc. filed a Form 8-K on November 20, 2026, disclosing that it entered into an Omnibus Amendment Agreement with PharmaCyte Biotech, Inc. to amend the terms of its Series G and Series H Convertible Preferred Stock certificates of designations and certain related warrants.

Key Highlights

  • Omnibus Agreement: On November 20, 2026, Q/C Technologies entered into the Omnibus Amendment Agreement with PharmaCyte Biotech, Inc., which holds at least a majority of the outstanding shares of each of the Series G and Series H Preferred Stock.
  • Amendments filed: The Series G Certificate of Designations Amendment and the Series H Certificate of Designations Amendment were each filed with the Delaware Secretary of State on November 20, 2026, and became effective upon filing.
  • Scope of changes: Both amendments revise the amendment provisions and the beneficial ownership limitations with respect to PharmaCyte; the Series G Long-Term Warrants held by PharmaCyte were also amended on the same points.
  • Maturity date extended: A separate Certificate of Amendment filed November 20, 2026, extends the maturity date of the Series H Preferred Stock from March 2, 2027 to September 2, 2027, pursuant to the Consent and Warrant Exchange Agreement dated November 15, 2026.
  • Series G background: The Series G Preferred Stock was originally issued under a Securities Purchase Agreement dated May 20, 2024, alongside five-year long-term warrants and warrants with an initial eighteen-month term.
  • Series H background: The Series H Preferred Stock was originally issued under a Securities Purchase Agreement dated September 2, 2025, together with accompanying warrants to purchase Common Stock.

Q/C Technologies and PharmaCyte Restructure Preferred Stock Terms in November 2026

According to the filing, Q/C Technologies, Inc. (NASDAQ:QCLS) entered into the Omnibus Amendment Agreement on November 20, 2026, with PharmaCyte Biotech, Inc. The filing describes PharmaCyte as holding "at least a majority of the outstanding shares of each of the Series G Preferred Stock and the Series H Preferred Stock," thereby constituting the Required Holders as defined under each certificate of designations. The agreement covers three sets of amendments: the Series G Certificate of Designations, the Series H Certificate of Designations, and the Series G Long-Term Warrants held by PharmaCyte.

The company disclosed that each of the Series G Amendment and the Series H Amendment modifies the amendment provisions set forth in those certificates and revises the beneficial ownership limitations applicable to PharmaCyte. Both amendments were filed with the Delaware Secretary of State on November 20, 2026, and the filing states that each "became effective with the Secretary of State upon filing." In addition, the Series G Long-Term Warrants held by PharmaCyte were amended to revise their amendment provisions and beneficial ownership limitation provisions.

Separately, the filing incorporates by reference disclosures from the company's Quarterly Report on Form 10-Q filed November 16, 2026, regarding a Consent and Warrant Exchange Agreement dated November 15, 2026. Under that prior agreement, PharmaCyte consented to extend the Series H Preferred Stock maturity date from March 2, 2027 to September 2, 2027. The corresponding Series H Maturity Amendment was filed with the Delaware Secretary of State on November 20, 2026. The filing notes that all descriptions of these agreements "do not purport to be complete" and are qualified by the full text of the exhibits filed with the report.

What Was Disclosed

Q/C Technologies disclosed the execution and filing of an Omnibus Amendment Agreement with PharmaCyte Biotech, Inc. amending the beneficial ownership limitations and amendment provisions of its Series G and Series H Preferred Stock certificates and related warrants, and extending the Series H maturity date to September 2, 2027.